



Published in final edited form as:

Trends Cell Biol. 2016 April ; 26(4): 300–312. doi:10.1016/j.tcb.2016.01.003.

Probing the complexities of astrocyte calcium signaling

Eiji Shigetomi¹, Sandip Patel², and Baljit S. Khakh^{3,4}

¹Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan

²Department of Cell and Developmental Biology, University College London, Gower Street, London WC1E 6BT; Department of Neurobiology David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA CA 90095-1751

³Department of Physiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA CA 90095-1751

⁴Department of Physiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA CA 90095-1751

Abstract

Astrocytes are abundant glial cells that tile the entire central nervous system and mediate well established functions for neurons, blood vessels and other glia. These ubiquitous cells display intracellular Ca^{2+} signals, which have been intensely studied for 25 years. Recently, the use of improved methods has unearthed the panoply of astrocyte Ca^{2+} signals and a variable landscape of basal Ca^{2+} levels. *In vivo* studies have started to reveal the settings under which astrocytes display behaviorally relevant Ca^{2+} signaling. Studies in mice have emphasized how astrocyte Ca^{2+} signaling is altered in distinct neurodegenerative diseases. Progress in the last few years, fueled by methodological advances, has thus reignited interest in astrocyte Ca^{2+} signaling for brain function and dysfunction.

Keywords

astrocyte; calcium; imaging; GCaMP; AAV

Introduction

Astrocytes tile the central nervous system and may represent ~20-40% of the total number of brain cells [1]. Their highly branched morphology, including proximity to neurons and blood vessels, has been the subject of intrigue, speculation and study ever since astrocytes

Correspondence to BSK: Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, 53-263 CHS, Los Angeles, CA 90095-1751, Fax: 310 206 5661, Tel : 310 825 6258, bkhakh@mednet.ucla.edu.

Author contributions: BSK, SP and ES worked on subsections separately. BSK drafted the final version and all authors commented and agreed on it.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

were discovered ~150 years ago. It is now well established that astrocytes serve diverse and important roles for the brain to function as an organ. These include roles for astrocytes in ion homeostasis, neurotransmitter clearance, synapse formation/removal, synaptic modulation and contributions to neurovascular coupling, all of which are reviewed elsewhere [2-4]. From these perspectives, attention has focussed on astrocyte intracellular Ca^{2+} signals as a basis to measure, interrogate and ultimately understand their roles within neural circuits [2, 5]. The strong focus on Ca^{2+} is based on the knowledge that Ca^{2+} is a widely used and important second messenger and on the realisation that astrocytes, unlike neurons, are electrically not excitable [6].

The possibility that astrocytes may contribute to neural circuit function was first proposed almost 25 years ago [7, 8], soon after astrocyte Ca^{2+} signals were discovered [5]. Since then astrocyte Ca^{2+} signals have been studied in detail. In this review, we focus on recent insights on the properties of astrocyte Ca^{2+} signals, on emerging studies of astrocyte basal Ca^{2+} levels and on their relation to two exemplar neurodegenerative disease models and behavior. Recent breakthroughs in the astrocyte field over the last few years have been fueled by technical advances that allow Ca^{2+} signals to be studied reliably in physiologically relevant compartments both *ex vivo* in brain slices and *in vivo* in adult mice.

Genetically-encoded calcium indicators (GECIs)

Organic Ca^{2+} indicator dyes, delivered to astrocytes by bulk loading or by intracellular dialysis using patch pipettes, have proven useful to study astrocytes [5]. Fundamental insights have emerged from their use [9-13]. These include the discovery of astrocyte Ca^{2+} signals [14-16] and two decades of work on their relation to neuronal activity [10, 17], including the first studies of astrocyte Ca^{2+} dynamics *in vivo* [18]. However, astrocytes are problematic to load with organic Ca^{2+} indicator dyes in adult brain slices. Moreover, *in vivo* repeated chronic imaging experiments are problematic because the dyes are lost from the cells over time, and organic dyes clearly only reveal the astrocyte's somata [19]. Hence additional approaches were needed. We focus here on recent studies employing GECIs, which comprise a single polypeptide chain of a fluorescent protein (or proteins) and a Ca^{2+} binding motif [20-22]. These largely overcome the aforementioned limitations of organic Ca^{2+} indicator dyes for the study of astrocytes.

Two types of GECIs have been used in astrocyte studies: single wavelength GECIs such as the GCaMP series (Figure 1), and FRET based ratiometric GECIs, such as the Yellow Cameleons [20]. GCaMPs are derived from circularly permuted enhanced GFP, the M13 peptide from myosin light chain kinase and calmodulin (Figure 1) [23]. In the absence of Ca^{2+} , GCaMPs display weak fluorescence, but upon Ca^{2+} binding (to calmodulin) increased green fluorescence is observed. GCaMPs have been optimized in terms of brightness, signal-to-noise, dynamic range, Ca^{2+} affinity and photostability [24-27]. The latest GCaMP6 series developed by the Janelia GENIE Project performs as well as some organic Ca^{2+} indicator dyes [24]. The properties of GCaMPs are further leveraged by targeting them to sub cellular compartments such as the plasma membrane [28-31], mitochondria [32-34] and endoplasmic reticulum [33, 35]. Ratiometric FRET based GECIs are also widely used and have been

improved to tune Ca^{2+} affinity to desirable levels [36]. The design and evolution of GECIs has been reviewed [20, 22].

GECIs have been targeted to astrocytes using several techniques, including *in utero* electroporation, adeno-associated viruses (AAVs), as well as transgenic and knock-in approaches (Table 1). These versatile proteins have features of relevance to astrocytes: i. cell specific targeting increases signal-to-noise, especially in relation to organic dyes [28]; ii. GECIs are stably expressed for weeks without noticeable deleterious effects, permitting chronic repeated imaging experiments *in vivo* [37, 38]; iii. GECIs generally display little bleaching during acute imaging experiments [28]; and iv. GECIs reveal Ca^{2+} signals from entire astrocytes [28]. Thus, GECIs overcome some of the limitations [5, 19] of organic Ca^{2+} indicators to study astrocytes.

GECIs are not a panacea, however, and they come with features and considerations that need to be taken into account for each experiment. Thus GECIs, like all Ca^{2+} indicators, have the potential to buffer Ca^{2+} and therefore alter astrocyte physiology. As far as we know, this has not proven to be a problem, but needs to be considered. The concentration of GECIs inside cells is largely unknown and is expected to differ between expression strategies (Table 1). A conservative estimate suggests that GECIs are expressed in the tens of micromolar concentration range [31]. Moreover, the affinity of available GECIs should be considered for each specific experiment; this parameter can be tuned by mutagenesis [39]. The on- and off-kinetics of many GECIs are slower than those of organic indicator dyes, but the GCaMP6 series is the fastest [24]. Of note, high expression of GFP in astrocytes is known to cause astrogliosis [40] and expression of GECIs over several months decreases the health of neurons [41]. Thus, long-term GECI expression in astrocytes may be problematic, especially with AAV-based expression methods [41]. Hence, GECI expression strategies need to be validated on a case-by-case basis as in published studies for cortex, hippocampus and striatum [28, 38, 42-44]. In addition, although AAV-mediated GECI delivery has proven powerful, one has to consider that surgical delivery of AAVs unavoidably damages brain tissue, and thus the cells that are imaged are usually located distally to the microinjection site. This strategy works well for large brain structures such as cortex, hippocampus and striatum, but may be problematic for small brain nuclei. In these cases, independent assessment of damage is needed. *In utero* electroporation has clear advantages for studying astrocytes during development, in neonatal mice and for rats for which gene targeting strategies are less well developed [31]. With the use of Cre-dependent knock-in mouse lines, one needs to consider the specificity of the Cre line and the proportion of astrocytes targeted in a given brain area. For example, GLAST-Cre/ERT2 targets GECIs to ~35% of astrocytes in the cortex, ~40% in the CA1 region of the hippocampus and close to 100% of Bergmann glia in the cerebellum [37, 38]. Most glial fibrillary acidic protein (GFAP)-Cre lines result in expression within populations of neurons and astrocytes and are not suited for expressing GECIs selectively within astrocytes [45, 46].

Ca^{2+} signals were recently compared for hippocampal astrocytes when GCaMP3 or GCaMP6f were expressed using AAV or using GCaMP3 and GCaMP6f knock-in mice [38, 43]. The data were indiscernible. Furthermore, GECIs have been deployed in several studies

and no untoward effects have been reported [26, 28-32, 37, 38, 42-44, 47-55]. In future astrocyte studies, appropriate controls will still be needed.

Astrocyte Ca²⁺ signals

Ca²⁺ signaling is a mature field in cell biology. Nonetheless, despite progress, major questions concerning astrocyte Ca²⁺ signaling remain to be satisfactorily addressed [5]. This is probably because multiple potential sources of Ca²⁺ have not been explored and hence not convincingly ruled in or out (Figure 2, Key Figure). These include receptors, channels, exchangers and pumps on the plasma membrane, as well as within intracellular organelles such as mitochondria, endoplasmic reticulum, Golgi and acidic organelles (Figure 2). These sources and sinks exploit Ca²⁺ concentration gradients between cellular compartments [58-60]. In going forward, it will be important to consider the possibility that astrocytes, like other cells, contain multiple sources of Ca²⁺ and that the relative contributions of each may change depending on the brain area [1, 61, 62]. Notably, recent cell specific proteomics shows that ~85% of proteins are shared between major brain cell types [63], implying that several plausible Ca²⁺ sources known to exist in other cell types merit detailed study in astrocytes (Figure 2).

Ca²⁺ release from intracellular stores—GECIs have been particularly valuable to study Ca²⁺ signals in astrocyte branches and branchlets that have previously been difficult to explore [64]. A major mechanism for generating Ca²⁺ signals is through activation of inositol triphosphate (IP₃) receptors which mediate Ca²⁺ release from the ER (Figure 2). Three isoforms of IP₃ receptors exist in vertebrates (IP3R1-3). IP3R2s are enriched in astrocytes [65] and because astrocytes respond to many G-protein coupled receptor (GPCR) agonists [66, 67] this IP3R2 mediated intracellular Ca²⁺ release pathway was expected to dominate. In accord, astrocytes that lacked IP3R2s appeared to lack spontaneous and GPCR-mediated Ca²⁺ signals [68] that were measured using organic Ca²⁺ indicators and Ca²⁺ signaling was reported to be “obliterated” in 100% of hippocampal astrocytes [68, 69]. The finding that the *Ip3r2*^{-/-} mice also displayed no obvious neuronal deficits led the authors to conclude that astrocyte Ca²⁺ signals were not involved in neuronal and behavioral responses [69, 70]. However, recent evaluations in brain slices and *in vivo* using the fast GECI GCaMP6f to measure Ca²⁺ signals in wild type and homozygous *Ip3r2*^{-/-} adult mice, have provided new insights [38]. First, the overall pattern of Ca²⁺ signals within astrocytes was similar between hippocampal astrocytes in slices and cortical astrocytes *in vivo* for both wild type and *Ip3r2*^{-/-} mice [38]. This shows that Ca²⁺ signals were not the consequence of the method employed, i.e. they were not detectably caused or altered by brain slice procedures. This is an important point, given past suggestions that astrocyte Ca²⁺ signaling was altered in brain slices under conditions used by some investigators [71]. Second, standardized semi-automated analyses of wild type and *Ip3r2*^{-/-} mice showed IP3R2-independent Ca²⁺ signaling within astrocyte branches [38, 43]. Similar residual Ca²⁺ signals in astrocyte branches have been reported by others [48] and available data suggest that most physiological Ca²⁺ signaling actually occurs mainly in astrocyte branches and branchlets [28, 43, 72]. Consistent with these data, roles for IP3R1 and 3 in mediating residual Ca²⁺ signals in astrocytes from *Ip3r2*^{-/-} mice has been suggested [73]. Strong stimuli were required to elicit somatic Ca²⁺ signals [43, 48, 72]. Consistent with these data, somatic Ca²⁺

signals were largely reduced in *Ip3r2*^{-/-} mice, but those in branches were only partially reduced (Figure 3) [38]. However, astrocyte Ca²⁺ signals evoked by neuronal glutamate release were abolished in *Ip3r2*^{-/-} mice [43]. Taken together, these findings suggest that the use of organic Ca²⁺ indicator dyes, which mainly reveal somatic compartments, led to the simplistic conclusion that spontaneous and GPCR-mediated Ca²⁺ signaling in astrocytes was abolished in *Ip3r2*^{-/-} mice. The discovery of residual Ca²⁺ signals in *Ip3r2*^{-/-} mice now necessitates the need for additional ways to impair Ca²⁺ signaling, for reevaluation of potential neuronal and cerebrovascular consequences [2] and for exploration of the full gamut of potential Ca²⁺ signals (Figure 2).

Ca²⁺ influx signals in astrocytes—Astrocytes interact with neurons via small finger-like structures [74, 75], which we term leaflets and branchlets. These display diameters on the tens of nanometer scale and are expected to have high surface area to volume ratios [76] and hence cannot be imaged directly with light microscopy. In addition, evanescent wave microscopy has shown that astrocytes display numerous near membrane Ca²⁺ signals [29, 30]. In light of these facts, the Lck tag has been used to recruit GECIs to the plasma membrane of astrocytes *in vitro* and *in vivo* following delivery with AAVs [28, 47] or *in utero* electroporation [31]. The Lck-tag is a 26 amino acid polypeptide including tandem myristoylation and palmitoylation domains - it results in essentially complete labeling of the astrocyte plasma membrane [77]. Lck-GCaMP3 revealed microdomain Ca²⁺ signals which occurred spontaneously and in a seemingly random fashion. These were termed “spotty Ca²⁺ signals” [29]. Pharmacological and genetic evaluations showed that spotty Ca²⁺ signals were mediated by Ca²⁺ influx through TRPA1 channels [30]. Subsequent slice experiments showed that they contributed to basal Ca²⁺ levels, which were necessary for the constitutive release of D-serine into the extracellular space [47] and for γ -aminobutyric acid (GABA) transporter expression on the plasma membrane [30]. The wide use of GECIs has revealed other examples of broadly similar spotty Ca²⁺ signals in astrocytes in brain slices and *in vivo*; frequently they are called microdomains. However, their molecular basis remains to be determined (Figure 2). For example, in the CA3 region of the hippocampus, TRPA1 channels did not mediate Ca²⁺ microdomains and those observed in stratum radiatum astrocytes were only partially blocked by a TRPA1 antagonist [43, 47]; TRPV1 channels could be usefully explored in this context based on cell culture studies [78]. Region specific differences may explain why astrocytes in different circuits display Ca²⁺ signals from different sources, of differing duration and separable reliance on neuronal action potential firing [13, 43, 79]. Evaluations with GCaMP6f in the hippocampus show that ~50% of spontaneous Ca²⁺ signals are dependent on transmembrane fluxes within astrocyte branches, but few if any are dependent on this pathway in the somata [38]. The spotty transmembrane fluxes probably locally elevate Ca²⁺ concentration by ~300 nM, whereas G-protein coupled receptors globally elevate Ca²⁺ to at least 1 μ M [29]. Further detailed molecular and biophysical analyses would be insightful.

Basal Ca²⁺ levels of astrocytes—In addition to Ca²⁺ signals, the basal Ca²⁺ level of cells is expected to be physiologically important. The basal level of Ca²⁺ within cultured hippocampal astrocytes was estimated to be ~120 nM using ratiometric Fura-2 imaging [29]. However, these methods are prone to several well-known artifacts when used in

complex tissues such as brain slices and *in vivo* (e.g. light absorption/scattering, movement, concentration inhomogeneities). As a result, the astrocyte basal Ca^{2+} concentration was estimated by 2-photon laser scanning microscopy (2PLSM) and fluorescence lifetime imaging microscopy (FLIM), an advanced method that measures the average time a fluorophore spends in the excited state before returning to the ground state [80]. The method overcomes many of the problems mentioned above, but requires specialized equipment. FLIM was used to measure the Ca^{2+} concentration of cortical astrocytes using Oregon Green BAPTA-1 (OGB-1) delivered by bulk loading *in vivo* [81]. The resting concentration of Ca^{2+} was found to be ~ 84 nM, but was significantly elevated to ~ 155 nM in mouse models of Alzheimer's disease. The potential molecular pathways that determine basal Ca^{2+} levels in cortical astrocytes are currently unknown (Figure 2).

FLIM has recently been used with a plumb in a recent study to map astrocyte basal Ca^{2+} concentrations in hippocampal brain slices and for the cortex *in vivo* [82]. The study exploited the observation that the fluorescence lifetime of OGB-1 increases with increasing concentration of Ca^{2+} in the nanomolar range [83, 84]. A number of fundamental observations were made. First, the basal Ca^{2+} concentration of astrocytes was markedly higher than that of neurons in hippocampal brain slices. Second, the Ca^{2+} concentration in astrocytes that were loaded with OGB-1 via gap junction coupling was ~ 100 nM near the soma, but increased to ~ 125 nM towards the edges of single astrocytes, i.e. in areas that correspond to branches (Figure 4) where there is greater preponderance of Ca^{2+} fluxes [28, 38, 43, 72]. Third, the astrocyte basal Ca^{2+} concentration decreased dramatically between the ages of 14 and 21 days throughout the cell, but nonetheless maintained an increasing gradient outward from the soma (Figure 4). This recalls previous observations on the differences between young and adult mice for Ca^{2+} signaling [85]. Fourth, when basal Ca^{2+} was measured in many dozens of astrocytes, the cells segregated into two populations: one with a mean basal Ca^{2+} concentration of ~ 70 -75 nM and another at ~ 120 -130 nM. This observation was unexpected and made possible only because of FLIM. Fifth, there was remarkable concordance across the board for data gathered *in vivo* and in acute brain slices, again suggesting that the judicious use of brain slices is a useful way to study astrocytes within semi intact preparations.

The realization that astrocyte basal Ca^{2+} levels are an important physiological attribute of astrocytes raises the all-important issue of their functional roles. In relation to this, work with brain slices prepares us for the possibility that changes in the basal Ca^{2+} concentration of astrocytes may have neuronal consequences by virtue of neurotransmitter uptake and D-serine release [30, 47]. Basal Ca^{2+} levels in astrocytes also play a key role in maintaining tonic blood flow by regulation of arteriole diameter [86]. More work is needed, but it is likely that additional functions of basal Ca^{2+} levels will emerge, for example setting of the sensitivity of Ca^{2+} sensitive Ca^{2+} release channels to activation upon GPCR engagement. The cytosol as an “excitable medium” in astrocytes might substitute for excitable behavior at the plasma membrane.

Astrocyte Ca²⁺ signaling in health and disease

Astrocyte Ca²⁺ signals in relation to behavior—Smith invoked the idea that astrocyte Ca²⁺ signals may affect the function of neural circuits [7, 8] and ultimately behavior. The use of GECIs and 2PLSM is now permitting exploration of this concept *in vivo* for whole astrocytes and entire fields of view containing many astrocytes, i.e. at sub cellular and macroscopic levels of investigation. The most relevant experiments are performed in awake behaving mice, because of the discovery that anesthesia largely abrogates astrocyte Ca²⁺ signals [87-89]. Astrocytes display robust Ca²⁺ elevations during locomotion. These were correlated in the cortex and Bergmann glia and reflect brain wide changes [37, 88]. The available data suggest that astrocytes respond to the endogenous release of noradrenaline during arousal or heightened vigilance states [37, 90]. Noradrenaline acts on α 1 adrenoceptors, which in the simplest interpretation are located on astrocytes [37, 38, 90-93], although other neuromodulators such as acetylcholine may also contribute [94, 95]. α 1 adrenoceptors could conceivably be located on another cell type and impact upon astrocytes indirectly. The responses were thus driven by a slow neuromodulator and were global in the sense that all astrocytes in the imaged field of view displayed elevations. Although abundant spontaneous Ca²⁺ signals in branches were observed [38], there was little evidence for local Ca²⁺ signals triggered selectively during startle responses, which implies that noradrenaline acts broadly as a volume transmitter. This effect of endogenously released noradrenaline was mainly, but not completely mediated by Ca²⁺ release from intracellular IP3R2-dependent Ca²⁺ stores [38]. Thus, a startle-evoked slow response persisted in astrocyte branches in the *Ip3r2*^{-/-} mice [38]. Interestingly, responses of layer 2/3 visual cortex astrocytes to light were enhanced markedly by enforced locomotion [37], which suggests that local (visual stimulation) and global (locomotion/arousal) signals may act synergistically through as yet unknown molecular mechanisms. However, further studies are needed to determine if astrocyte responses during arousal have any relation to the change in gain of primary visual cortex layer 2/3 neurons during locomotion [96, 97], or if astrocyte responses mediated by noradrenaline can affect cortical synaptic function. The kinetics of the astrocyte responses appear too slow to affect the gain change of cortical neurons [37, 38], but refined tools to abolish astrocyte Ca²⁺ signals selectively and locally in the cortex are needed to explore this issue. Moreover, given that astrocytes are considered to be heterogeneous [62], future studies will need to evaluate astrocyte Ca²⁺ responses *in vivo* in genetically defined populations of astrocytes and also in deeper brain structures during ethologically relevant behaviors. Such studies will benefit immensely from the use of wearable endoscopes in combination with red shifted GECIs to permit imaging deeper into tissue [98]. Calcium integrators such as CaMPARI are also likely to be valuable [99].

Astrocyte Ca²⁺ signaling and neurodegenerative disease—It has been proposed that glia contribute to brain disease [100], and more specifically that astrocyte Ca²⁺ signals may participate in neurological and psychiatric disorders [101]. We emphasize recent evaluations in mouse models of two distinct neurodegenerative diseases in which astrocyte Ca²⁺ signaling was altered in separable ways.

Pioneering studies using FLIM in a mouse model of familial Alzheimer's disease (AD) showed that astrocytes displayed higher basal astrocyte Ca²⁺ levels and increased transient

Ca²⁺ signals, which may represent a heightened Ca²⁺ signaling phenotype [81]. However, although it has been proposed that astrocyte Ca²⁺ signals can be triggered by action potential firing in some brain areas [5], within the cortex *in vivo* neither normal nor heightened Ca²⁺ signaling in AD model mice was the result of action potential firing in neurons [102]. The best available data show that heightened Ca²⁺ signaling arose because reactive astrocytes were located near β -amyloid plaques and because they displayed enhanced extracellular ATP-dependent P2Y1-receptor mediated Ca²⁺ signaling [102]. In support, heightened Ca²⁺ signaling could be blocked by pharmacological interventions that blocked ATP release from connexin hemi channels and by P2Y1 receptors antagonists [102]. Taken together, these data indicate that heightened astrocyte Ca²⁺ signals that accompany pathology in mouse models of AD may be caused by a combination of ATP release and/or increased P2Y1 receptor expression by a population of reactive astrocytes located near plaques. If so, P2Y1 receptors may represent a novel therapeutic target for AD. In addition, it is of great interest, and worthy of further evaluations *in vivo*, that direct application of low amounts of amyloid- β peptides to astrocytes can enhance astrocyte Ca²⁺ signals via a mechanism involving α 7 nicotinic receptors [103, 104].

Several previous studies have implicated astrocytes in Huntington's disease (HD) [105-109]. Astrocyte Ca²⁺ signals have thus recently been explored in a mouse model of HD[110]. Notably, at the ages tested, HD model mice did not display astrogliosis [109] and thus the underlying changes that occur are separable from those observed in AD model mice, which are strongly associated with astrogliosis [102]. The experiments were conducted on striatal astrocytes in adult mice at early stages of symptom onset before overt tissue loss [110]. Wild type striatal astrocytes displayed extensive spontaneous Ca²⁺ signals, but did not respond reliably with Ca²⁺ elevations during synaptic glutamate release from cortical inputs [110]. In contrast, in HD model mice, spontaneous Ca²⁺ signals were significantly reduced in amplitude, frequency and duration, but astrocytes responded robustly to cortical stimulation with evoked action potential dependent Ca²⁺ signals [110]. The available data suggest that these evoked Ca²⁺ signals were accompanied by prolonged extracellular glutamate levels that activated mGluR2/3 receptors on astrocytes to cause Ca²⁺ release from intracellular stores. In this view, astrocyte engagement was tightly gated by Glt1 glutamate transporters, which presumably normally function to clear extracellular glutamate before it can reach astrocyte mGluR2/3 receptors. Interestingly, Ca²⁺ and glutamate signaling in astrocytes from HD model mice was rescued by astrocyte specific restoration of Kir4.1, which past studies show was reduced in HD and contributed to disease phenotypes [109]. These data imply that astrocyte contributions to HD model mice involve intimate functional interactions between two homeostatic pathways: K⁺ buffering and glutamate clearance. The reduction of these in HD results in dramatically altered Ca²⁺ signaling, but it remains to be determined if altered astrocyte Ca²⁺ signaling directly contributes to neuronal deficits in HD or if these are mainly modulated by altered K⁺ and glutamate levels. Nonetheless, early astrocyte dysfunctions that precede astrogliosis may represent novel therapeutic targets in HD. More broadly, it is of interest mechanistically that two neurodegenerative diseases are accompanied by distinctly altered astrocyte Ca²⁺ signaling [81, 102, 110]. This raises the possibility that astrocyte Ca²⁺ signaling contributes in very specific ways to specific brain disorders.

Concluding remarks

An important goal of modern neuroscience is to understand how neurons and neural circuits give rise to complex behaviors. This is one of the oldest questions in neurobiology, but the tools of modern biology now make it experimentally tractable. It is tempting to also ask how astrocytes contribute to neural circuits that underlie behavior. Such experiments are certainly needed and are underway [17, 111], but one ought to also consider the possibility that astrocytes may largely provide an appropriate substrate and milieu for neurons to perform their multifarious operations. Such astrocyte functions could be indispensable [100], but perhaps not directly related to the computations neurons perform to give rise to behavior *per se*. If this proves to be the case, and experiments are needed to prove or refute this idea, it may instead be productive to ask how astrocyte dysfunction drives neural circuit malfunction and how this contributes to phenotypic manifestations of disease. In other words, perhaps astrocyte dysfunctions drive disease mechanisms, but in otherwise healthy tissue astrocytes normally provide sustenance and a fabric on which neural circuits form and work. In these settings, astrocytes may be amenable to selective pharmacological, genetic and remote manipulation, or even replacement [112], with the goal of producing desirable effects within neural circuits to modify disease symptoms and outcomes. Early examples of such strategies are emerging and could be explored in other disorders [102, 109, 110, 112]. We believe this is a useful and new conceptual framework within which to consider astrocyte Ca^{2+} signals, however, it should also be considered that astrocytes regulate synaptic function as well as participate in and contribute to global brain states. Both of these existing ideas have been extensively reviewed already [17, 113]. Future research will be immeasurably advanced with the detailed understanding of astrocyte molecular mechanisms and the availability of methods with which to study additional aspects of astrocyte signaling. Many important questions remain unanswered in this field (see Outstanding Questions).

The last few years have witnessed vigorous debate on the physiological role(s) of astrocyte Ca^{2+} signals and if, how, why and when they contribute to neural circuit function. A summary of the relevant issues is provided by Bazargani and Attwell [2]. Recent advances with monitoring Ca^{2+} signals selectively within physiologically relevant astrocyte compartments in brain slices and *in vivo* for adult mice have now provided a more nuanced view of astrocyte Ca^{2+} signals and their relations to synaptic and neural circuit function. Many of these insights derive from the use of much improved methods. Taken together, these technique driven insights are fueling a new wave of astrocyte research [2] and stimulating new ideas. We are reminded of Sydney Brenner's insightful adage: "*Progress in science depends on new techniques, new discoveries and new ideas, probably in that order*".

Acknowledgments

Work in the Khakh lab is supported by the CHDI Foundation and by NIH grants NS060677, MH099559 and MH104069. Eiji Shigetomi is supported by JSPS KAKENHI 25710005 and Takeda Science Foundation. Work in the Patel lab is supported by the BBSRC and Parkinson's UK. Thanks to Dmitri Rusakov (UCL) for permission to use Figure 4, the Janelia GENIE Project for help to make Figure 1 and David Attwell (UCL) for sharing unpublished work. The authors regret that many papers could not be cited (especially early pioneering studies), because of space limits and the editorial requirement to focus on studies from the last five years.

References

1. Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. *Nat Neurosci.* 2015; 18:942–952. [PubMed: 26108722]
2. Bazargani N, Attwell D. Astrocyte calcium signalling: the third wave. *Nat Neurosci.* 2015 accepted.
3. Chung WS, Allen NJ, Eroglu C. Astrocytes Control Synapse Formation, Function, and Elimination. *Cold Spring Harb Perspect Biol.* Feb 6.2015 7(9) pii: a020370.
4. Haydon PG, Nedergaard M. How do astrocytes participate in neural plasticity? *Cold Spring Harb Perspect Biol.* Dec 11.2014 7(3):a020438. [PubMed: 25502516]
5. Khakh BS, McCarthy KD. Astrocyte calcium signaling: from observations to functions and the challenges therein. *Cold Spring Harb Perspect Biol.* Jan 20.2015 7(4):a020404. [PubMed: 25605709]
6. Olsen ML, Khakh BS, Skatchkov SN, Zhou M, Lee CJ, Rouach N. New Insights on Astrocyte Ion Channels: Critical for Homeostasis and Neuron-Glia Signaling. *J Neurosci.* 2015; 35:13827–13835. [PubMed: 26468182]
7. Smith SJ. Do astrocytes process neural information? *Prog Brain Res.* 1992; 94:119–136. [PubMed: 1337609]
8. Smith S. Neural signalling. Neuromodulatory astrocytes. *Curr Biol.* 1994; 4:807–810. [PubMed: 7820550]
9. Rusakov DA. Disentangling calcium-driven astrocyte physiology. *Nat Rev Neurosci.* 2015; 16:226–233. [PubMed: 25757560]
10. Volterra A, Liaudet N, Savtchouk I. Astrocyte Ca(2+)(+) signalling: an unexpected complexity. *Nat Rev Neurosci.* 2014; 15:327–335. [PubMed: 24739787]
11. Grosche J, Matyash V, Möller T, Verkhratsky A, Reichenbach A, Kettenmann H. Microdomains for neuron-glia interaction: parallel fiber signaling to Bergmann glial cells. *Nat Neurosci.* 1999; 2
12. Di Castro MA, Chuquet J, Liaudet N, Bhaukaurally K, Santello M, Bouvier D, Tiret P, Volterra A. Local Ca²⁺ detection and modulation of synaptic release by astrocytes. *Nat Neurosci.* 2011; 14:1276–1284. [PubMed: 21909085]
13. Panatier A, Vallée J, Haber M, Murai KK, Lacaille JC, Robitaille R. Astrocytes are endogenous regulators of basal transmission at central synapses. *Cell.* 2011; 146:785–798. [PubMed: 21855979]
14. Dani JW, Chernjavsky A, Smith SJ. Neuronal activity triggers calcium waves in hippocampal astrocyte networks. *Neuron.* 1992; 8:429–440. [PubMed: 1347996]
15. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling. *Science.* 1990; 247:470–473. [PubMed: 1967852]
16. Charles AC, Merrill JE, Dirksen ER, Sanderson MJ. Intercellular signaling in glial cells: calcium waves and oscillations in response to mechanical stimulation and glutamate. *Neuron.* 1991; 6:983–992. [PubMed: 1675864]
17. Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A. Gliotransmitters travel in time and space. *Neuron.* 2014; 81:728–739. [PubMed: 24559669]
18. Hirase H, Qian L, Bartho P, Buzsaki G. Calcium dynamics of cortical astrocytic networks in vivo. *PLoS Biol.* 2004; 2:E96. [PubMed: 15094801]
19. Tong X, Shigetomi E, Looger LL, Khakh BS. Genetically encoded calcium indicators and astrocyte calcium microdomains. *Neuroscientist.* 2013; 19:274–291. [PubMed: 23264008]
20. Broussard GJ, Liang R, Tian L. Monitoring activity in neural circuits with genetically encoded indicators. *Front Mol Neurosci.* Dec 5.2014 7:97. eCollection 2014. [PubMed: 25538558]
21. Russell JT. Imaging calcium signals in vivo: a powerful tool in physiology and pharmacology. *Br J Pharmacol.* 2011; 163:1605–1625. [PubMed: 20718728]
22. Hires SA, Tian L, Looger LL. Reporting neural activity with genetically encoded calcium indicators. *Brain Cell Biol.* 2008; 36:69–86. [PubMed: 18941901]
23. Nakai J, Ohkura M, Imoto K. A high signal-to-noise Ca(2+) probe composed of a single green fluorescent protein. *Nat Biotechnol.* 2001; 19:137–141. [PubMed: 11175727]

24. Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, Schreiter ER, Kerr RA, Orger MB, Jayaraman V, Looger LL, Svoboda K, Kim DS. Ultrasensitive fluorescent proteins for imaging neuronal activity. *Nature*. 2013; 499:295–300. [PubMed: 23868258]
25. Tian L, Hires SA, Mao T, Huber D, Chiappe ME, Chalasani SH, Petreanu L, Akerboom J, McKinney SA, Schreiter ER, Bargmann CI, Jayaraman V, Svoboda K, Looger LL. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. *Nat Methods*. 2009; 6:875–881. [PubMed: 19898485]
26. Akerboom J, Chen TW, Wardill TJ, Tian L, Marvin JS, Mutlu S, Calderon NC, Eposti F, Borghius BG, Sun XR, Gordus A, Orger MB, Portugues R, Engert F, Macklin JJ, Filosa A, Aggarwal A, Kerr R, Takagi R, Kracun S, Shigetomi E, Khakh BS, Baier H, Lagnado L, Wang SSH, Bargmann CI, Kimmel BE, Jayaraman V, Svoboda K, Kim DS, S ER, Looger LL. Optimisation of a GCaMP Calcium Indicator for Neural Activity Imaging. *J Neurosci*. 2012; 32:13819–13840. [PubMed: 23035093]
27. Ohkura M, Sasaki T, Sadakari J, Gengyo-Ando K, Kagawa-Nagamura Y, Kobayashi C, Ikegaya Y, Nakai J. Genetically encoded green fluorescent Ca²⁺ indicators with improved detectability for neuronal Ca²⁺ signals. *PLoS One*. 2012; 7(12):e51286. Epub 2012 Dec 11. [PubMed: 23240011]
28. Shigetomi E, Bushong EA, Haustein MD, Tong X, Jackson-Weaver O, Kracun S, Xu J, Sofroniew MV, Ellisman MH, Khakh BS. Imaging calcium microdomains within entire astrocyte territories and endfeet with GCaMPs expressed using adeno-associated viruses. *J Gen Physiol*. 2013; 141:633–647. [PubMed: 23589582]
29. Shigetomi E, Kracun S, Sofroniew MV, Khakh BS. A genetically targeted optical sensor to monitor calcium signals in astrocyte processes. *Nat Neurosci*. 2010; 13:759–766. [PubMed: 20495558]
30. Shigetomi E, Tong X, Kwan KY, Corey DP, Khakh BS. TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. *Nat Neurosci*. 2012; 15:70–80. [PubMed: 22158513]
31. Gee JM, Gibbons MB, Taheri M, Palumbos S, Morris SC, Smeal RM, Flynn KF, Economo MN, Cizek CG, Capecci MR, Tvrdik P, Wilcox KS, White JA. Imaging activity in astrocytes and neurons with genetically encoded calcium indicators following in utero electroporation. *Front Mol Neurosci*. Apr 15.2015 8:10. eCollection 2015. [PubMed: 25926768]
32. Li H, Wang X, Zhang N, Gottipati MK, Parpura V, Ding S. Imaging of mitochondrial Ca²⁺ dynamics in astrocytes using cell-specific mitochondria-targeted GCaMP5G/6s: mitochondrial Ca²⁺ uptake and cytosolic Ca²⁺ availability via the endoplasmic reticulum store. *Cell Calcium*. 2014; 56:457–466. [PubMed: 25443655]
33. Suzuki J, Kanemaru K, Ishii K, Ohkura M, Okubom Y, Iino M. Imaging intraorganellar Ca²⁺ at subcellular resolution using CEPIA. *Nat Commun*. Jun 13.2014 5:4153. [PubMed: 24923787]
34. Zhao Y, Araki S, Wu J, Teramoto T, Chang YF, Nakano M, Abdelfattah AS, Fujiwara M, Ishihara T, Nagai T, Campbell RE. An expanded palette of genetically encoded Ca²⁺ indicators. *Science*. 2011; 333:1888–1891. [PubMed: 21903779]
35. Henderson MJ, Baldwin HA, Werley CA, Boccardo S, Whitaker LR, Yan X, Holt GT, Schreiter ER, Looger LL, Cohen AE, Kim DS, Harvey BK. A Low Affinity GCaMP3 Variant (GCaMPer) for Imaging the Endoplasmic Reticulum Calcium Store. *PLoS One*. Oct 9.2015 10(10):e0139273. eCollection 2015. [PubMed: 26451944]
36. Horikawa K, Yamada Y, Matsuda T, Kobayashi K, Hashimoto M, Matsu-ura T, Miyawaki A, Michikawa T, Mikoshiba K, Nagai T. Spontaneous network activity visualized by ultrasensitive Ca(2+) indicators, yellow Cameleon-Nano. *Nat Methods*. 2010; 7:729–732. [PubMed: 20693999]
37. Paukert M, Agarwal A, Cha J, Doze VA, Kang JU, Bergles DE. Norepinephrine controls astroglial responsiveness to local circuit activity. *Neuron*. 2014; 82:1263–1270. [PubMed: 24945771]
38. Srinivasan R, Huang BS, Venugopal S, Johnston AD, Chai H, Zeng H, Golshani P, Khakh BS. Ca(2+) signaling in astrocytes from Ip3r2(-/-) mice in brain slices and during startle responses in vivo. *Nat Neurosci*. 2015; 18:708–717. [PubMed: 25894291]
39. Sun XR, Badura A, Pacheco DA, Lynch LA, Schneider ER, Taylor MP, Hogue IB, Enquist LW, Murthy M, Wang SS. Fast GCaMPs for improved tracking of neuronal activity. *Nat Commun*. 2013; 4:2170. [PubMed: 23863808]

40. Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, Haydon PG, Coulter DA. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. *Nat Neurosci*. 2010; 13:584–591. [PubMed: 20418874]
41. Zariwala HA, Borghuis BG, Hoogland TM, Madisen L, Tian L, De Zeeuw CI, Zeng H, Looger LL, Svoboda K, Chen TW. A Cre-dependent GCaMP3 reporter mouse for neuronal imaging in vivo. *J Neurosci*. 2012; 32:3131–3141. [PubMed: 22378886]
42. Jiang R, Hausteine MD, Sofroniew MV, Khakh BS. Imaging intracellular Ca²⁺ signals in striatal astrocytes from adult mice using genetically-encoded calcium indicators. *J Vis Exp*. Nov 19.2014 (93):e51972. [PubMed: 25490346]
43. Hausteine MD, Kracun S, Lu XH, Shih T, Jackson-Weaver O, Tong X, Xu J, Yang XW, O'Dell TJ, Marvin JS, Ellisman MH, Bushong EA, Looger LL, Khakh BS. Conditions and constraints for astrocyte calcium signaling in the hippocampal mossy fiber pathway, *Neuron*. 2014; 82:413–429.
44. Bonder DE, McCarthy KD. Astrocytic Gq-GPCR-linked IP3R-dependent Ca²⁺ signaling does not mediate neurovascular coupling in mouse visual cortex in vivo. *J Neurosci*. 2014; 34:13139–13150. [PubMed: 25253859]
45. Sofroniew MV. Transgenic techniques for cell ablation or molecular deletion to investigate functions of astrocytes and other GFAP-expressing cell types. *Methods Mol Biol*. 2012; 814:531–544. [PubMed: 22144330]
46. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. *Nat Neurosci*. 2004; 7:1233–1241. [PubMed: 15494728]
47. Shigetomi E, Jackson-Weaver O, Huckstepp RT, O'Dell TJ, Khakh BS. TRPA1 channels are regulators of astrocyte basal calcium levels and long-term potentiation via constitutive D-serine release. *J Neurosci*. 2013; 33:10143–10153. [PubMed: 23761909]
48. Kanemaru K, Sekiya H, Xu M, Satoh K, Kitajima N, Yoshida K, Okubo Y, Sasaki T, Moritoh S, Hasuwa H, Mimura M, Horikawa K, Matsui K, Nagai T, Ino M, Tanaka KF. In vivo visualization of subtle, transient, and local activity of astrocytes using an ultrasensitive Ca(2+) indicator. *Cell Rep*. 2014; 8:311–318. [PubMed: 24981861]
49. Atkin SD, Patel S, Kocharyan A, Holtzclaw LA, Weerth SH, Schram V, Pickel J, Russell JT. Transgenic mice expressing a cameleon fluorescent Ca²⁺ indicator in astrocytes and Schwann cells allow study of glial cell Ca²⁺ signals in situ and in vivo. *J Neurosci Methods*. 2009; 181:212–226.
50. Tang W, Szokol K, Jensen V, Enger R, Trivedi CA, Hvalby Ø, Helm PJ, Looger LL, Sprengel R, Nagelhus EA. Stimulation-evoked Ca²⁺ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. *J Neurosci*. 2015; 35:3016–3021. [PubMed: 25698739]
51. Enger R, Tang W, Vindedal GF, Jensen V, Johannes Helm P, Sprengel R, Looger LL, Nagelhus EA. Dynamics of Ionic Shifts in Cortical Spreading Depression. *Cereb Cortex*. 2015; 25:4469–4476. [PubMed: 25840424]
52. Szokol K, Heuser K, Tang W, Jensen V, Enger R, Bedner P, Steinhäuser C, Taubøll E, Ottersen OP, Nagelhus EA. Augmentation of Ca(2+) signaling in astrocytic endfeet in the latent phase of temporal lobe epilepsy. *Front Cell Neurosci*. Feb 25.2015 9:49. eCollection 2015. [PubMed: 25762896]
53. Gee JM, Smith NA, Fernandez FR, Economo MN, Brunert D, Rothermel M, Morris SC, Talbot A, Palumbos S, Ichida JM, Shepherd JD, West PJ, Wachowiak M, Capecchi MR, Wilcox KS, White JA, Tvrdik P. Imaging activity in neurons and glia with a Polr2a-based and cre-dependent GCaMP5G-IRES-tdTomato reporter mouse. *Neuron*. 2014; 83:1058–1072. [PubMed: 25155958]
54. Akerboom J, Carreras Calderon N, Tian L, Wabnig S, Prigge M, Tolo J, Gordus A, Orger MB, Severi KE, Macklin JJ, Patel R, Pulver SR, Wardill TJ, Fischer E, Schuler C, Chen TW, Sarkisyan KS, Marvin JS, Bargmann CI, Kim DS, Kugler S, Lagnado L, Hegemann P, Gottschalk A, Schreiter ER, Looger LL. Genetically encoded calcium indicators for multi-color neural activity imaging and combination with optogenetics. *Front Mol Neurosci*. 2013; 6:2. [PubMed: 23459413]
55. Shigetomi E, Kracun S, Khakh BS. Monitoring astrocyte calcium microdomains with improved membrane targeted GCaMP reporters. *Neuron Glia Biol*. 2010; 6:183–191. [PubMed: 21205365]

56. Madisen L, Garner AR, Shimaoka D, Chuong AS, Klapoetke NC, Li L, van der Bourg A, Niino Y, Egolf L, Monetti C, Gu H, Mills M, Cheng A, Tasic B, Nguyen TN, Sunkin SM, Benucci A, Nagy A, Miyawaki A, Helmchen F, Empson RM, Knöpfel T, Boyden ES, Reid RC, Carandini M, Zeng H. Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. *Neuron*. 2015; 85:942–958. [PubMed: 25741722]
57. Nagai T, Yamada S, Tominaga T, Ichikawa M, Miyawaki A. Expanded dynamic range of fluorescent indicators for Ca²⁺ by circularly permuted yellow fluorescent proteins. *Proc Natl Acad Sci U S A*. 2004; 101:10554–10559. [PubMed: 15247428]
58. Patel S, Docampo R. Acidic calcium stores open for business: expanding the potential for intracellular Ca²⁺ signaling. *Trends Cell Biol*. 2010; 20:277–286. [PubMed: 20303271]
59. Miyawaki A, Llopis J, Heim R, McCaffery JM, Adams JA, Ikura M, Tsien RY. Fluorescent indicators for Ca²⁺ based on green fluorescent proteins and calmodulin. *Nature*. 1997; 388:882–887. [PubMed: 9278050]
60. Hill JM, De Stefani D, Jones AW, Ruiz A, Rizzuto R, Szabadkai G. Measuring baseline Ca²⁺ levels in subcellular compartments using genetically engineered fluorescent indicators. *Methods Enzymol*. 2014; 543:47–72. [PubMed: 24924127]
61. Oberheim NA, Goldman SA, Nedergaard M. Heterogeneity of astrocytic form and function. *Methods Mol Biol*. 2012; 814:23–45. [PubMed: 22144298]
62. Zhang Y, Barres BA. Astrocyte heterogeneity: an underappreciated topic in neurobiology. *Curr Opin Neurobiol*. 2010; 20:588–594. [PubMed: 20655735]
63. Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ, Mann M, Simons M. Cell type- and brain region-resolved mouse brain proteome. *Nat Neurosci*. Nov 2.2015 Epub ahead of print.
64. Reeves AM, Shigetomi E, Khakh BS. Bulk loading of calcium indicator dyes to study astrocyte physiology: key limitations and improvements using morphological maps. *J Neurosci*. 2011; 31:9353–9358. [PubMed: 21697385]
65. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. *J Neurosci*. 2008; 28:264–278. [PubMed: 18171944]
66. Fiacco TA, Agulhon C, McCarthy KD. Sorting out astrocyte physiology from pharmacology. *Annu Rev Pharmacol Toxicol*. 2009; 49:151–174. [PubMed: 18834310]
67. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. *Prog Neurobiol*. 1997; 51:439–455. [PubMed: 9106901]
68. Petracvic J, Fiacco TA, McCarthy KD. Loss of IP₃ receptor-dependent Ca²⁺ increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. *J Neurosci*. 2008; 28:4967–4973. [PubMed: 18463250]
69. Agulhon C, Fiacco TA, McCarthy KD. Hippocampal short- and long-term plasticity are not modulated by astrocyte Ca²⁺ signaling. *Science*. 2010; 327:1250–1254. [PubMed: 20203048]
70. Petracvic J, Boyt KM, McCarthy KD. Astrocyte IP₃R2-dependent Ca²⁺ signaling is not a major modulator of neuronal pathways governing behavior. *Front Behav Neurosci*. Nov 12.2014 8:384. eCollection 2014. [PubMed: 25429263]
71. Takano T, He W, Han X, Wang F, Xu Q, Wang X, Oberheim Bush NA, Cruz N, Dienel GA, Nedergaard M. Rapid manifestation of reactive astrogliosis in acute hippocampal brain slices. *Glia*. 2014; 62:78–95. [PubMed: 24272704]
72. Otsu Y, Couchman K, Lyons DG, Collot M, Agarwal A, Mallet JM, Pfrieder FW, Bergles DE, Chappak S. Calcium dynamics in astrocyte processes during neurovascular coupling. *Nat Neurosci*. 2015; 18:210–218. [PubMed: 25531572]
73. Sherwood MW, Arizono M, Hisatsune C, Bannai H, Ebisui E, Sherwood JL, Panatier A, Oliet SH, Mikoshiba K. Dissecting the role of IP₃-Receptor subtypes in hippocampal LTP. *Society for Neuroscience Abstract* 297.04/B89. 2015
74. Ventura R, Harris KM. Three-dimensional relationships between hippocampal synapses and astrocytes. *J Neurosci*. 1999; 19:6897–6906. [PubMed: 10436047]

75. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci*. 2002; 22:183–192. [PubMed: 11756501]
76. Hama K, Arai T, Katayama E, Marton M, Ellisman MH. Tri-dimensional morphometric analysis of astrocytic processes with high voltage electron microscopy of thick Golgi preparations. *J Neurocytol*. 2004; 33:277–285. [PubMed: 15475683]
77. Benediktsson AM, Schachtele SJ, Green SH, Dailey ME. Ballistic labeling and dynamic imaging of astrocytes in organotypic hippocampal slice cultures. *J Neurosci Methods*. 2005; 141:41–53. [PubMed: 15585287]
78. Ho KW, Lambert WS, Calkins DJ. Activation of the TRPV1 cation channel contributes to stress-induced astrocyte migration. *Glia*. 2014; 62:1435–1451. [PubMed: 24838827]
79. Di Castro MA, Chuquet J, Liaudet N, Bhaukaurally K, Santello M, Bouvier D, Tiret P, Volterra A. Local Ca²⁺ detection and modulation of synaptic release by astrocytes. *Nat Neurosci*. 2011; 10:1276–1284. [PubMed: 21909085]
80. Lakowicz, JR. Principles of fluorescence spectroscopy. 3rd. Springer; 2006.
81. Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. *Science*. 2009; 323:1211–1215. [PubMed: 19251629]
82. Zheng K, Bard L, Reynolds JP, King C, Jensen TP, Gourine AV, Rusakov DA. Time-Resolved Imaging Reveals Heterogeneous Landscapes of Nanomolar Ca(2+) in Neurons and Astroglia. *Neuron*. 2015; 88:277–288. [PubMed: 26494277]
83. Wilms CD, Schmidt H, Eilers J. Quantitative two-photon Ca²⁺ imaging via fluorescence lifetime analysis. *Cell Calcium*. 2006; 40:73–79. [PubMed: 16690123]
84. Wilms CD, Eilers J. Photo-physical properties of Ca²⁺-indicator dyes suitable for two-photon fluorescence-lifetime recordings. *J Microsc*. 2007; 225:209–213. [PubMed: 17371443]
85. Sun W, McConnell E, Pare JF, Xu Q, Chen M, Peng W, Lovatt D, Han X, Smith Y, Nedergaard M. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. *Science*. 2013; 339:197–200. [PubMed: 23307741]
86. Rosenegger DG, Tran CH, W C Ji, Gordon GR. Tonic Local Brain Blood Flow Control by Astrocytes Independent of Phasic Neurovascular Coupling. *J Neurosci*. 2015; 35:13463–13474. [PubMed: 26424891]
87. Thrane AS, Rangroo Thrane V, Zeppenfeld D, Lou N, Xu Q, Nagelhus EA, Nedergaard M. General anesthesia selectively disrupts astrocyte calcium signaling in the awake mouse cortex. *Proc Natl Acad Sci U S A*. 2012; 109:18974–18979. [PubMed: 23112168]
88. Nimmerjahn A, Mukamel EA, Schnitzer MJ. Motor behavior activates Bergmann glial networks. *Neuron*. 2009; 62:400–412. [PubMed: 19447095]
89. Schummers J, Yu H, Sur M. Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. *Science*. 2008; 320:1638–1643. [PubMed: 18566287]
90. Ding F, O'Donnell J, Thrane AS, Zeppenfeld D, Kang H, Xie L, Wang F, Nedergaard M. alpha1-Adrenergic receptors mediate coordinated Ca²⁺ signaling of cortical astrocytes in awake, behaving mice. *Cell Calcium*. 2013; 54:387–394. [PubMed: 24138901]
91. Bekar LK, He W, Nedergaard M. Locus coeruleus alpha-adrenergic-mediated activation of cortical astrocytes in vivo. *Cereb Cortex*. 2008; 18:2789–2795. [PubMed: 18372288]
92. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]_i. *Neurochem Int*. 2010; 57:411–420. [PubMed: 20380860]
93. Gordon GR, Baimoukhametova DV, Hewitt SA, Rajapaksha WR, Fisher TE, Bains JS. Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. *Nat Neurosci*. 2005; 8:1078–1086. [PubMed: 15995701]
94. Takata N, Mishima T, Hisatsune C, Nagai T, Ebisui E, Mikoshiba K, Hirase H. Astrocyte calcium signaling transforms cholinergic modulation to cortical plasticity in vivo. *J Neurosci*. 2011; 31:18155–18165. [PubMed: 22159127]

95. Chen N, Sugihara H, Sharma J, Perea G, Petravicz J, Le C, Sur M. Nucleus basalis-enabled stimulus-specific plasticity in the visual cortex is mediated by astrocytes. *Proc Natl Acad Sci U S A*. 2010; 109:E2832–2841. [PubMed: 23012414]
96. Niell CM, Stryker MP. Modulation of visual responses by behavioral state in mouse visual cortex. *Neuron*. 2010; 65:472–479. [PubMed: 20188652]
97. Keller GB, Bonhoeffer T, Hübener M. Sensorimotor mismatch signals in primary visual cortex of the behaving mouse. *Neuron*. 2012; 74:809–815. [PubMed: 22681686]
98. Hamel EJ, Grewe BF, Parker JG, Schnitzer MJ. Cellular level brain imaging in behaving mammals: an engineering approach. *Neuron*. 2015; 86:140–159. [PubMed: 25856491]
99. Fosque BF, Sun Y, Dana H, Yang CT, Ohyama T, Tadross MR, Patel R, Zlatic M, Kim DS, Ahrens MB, Jayaraman V, Looger LL, Schreier ER. Neural circuits. Labeling of active neural circuits in vivo with designed calcium integrators. *Science*. 2015; 347:755–760. [PubMed: 25678659]
100. Chung WS, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? *Nat Neurosci*. 2015; 18:1539–1545. [PubMed: 26505565]
101. Nedergaard M, Rodríguez JJ, Verkhratsky A. Glial calcium and diseases of the nervous system. *Cell Calcium*. 2010; 47:140–149. [PubMed: 20045186]
102. Delekate A, Füchtmeier M, Schumacher T, Ulbrich C, Foddis M, Petzold GC. Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model. *Nat Commun*. 2014; 5:5422. [PubMed: 25406732]
103. Lee L, Kosuri P, Arancio O. Picomolar amyloid- β peptides enhance spontaneous astrocyte calcium transients. *J Alzheimers Dis*. 2014; 38:49–62. [PubMed: 23948929]
104. Pirttimäki TM, Codadu NK, Awni A, Pratik P, Nagel DA, Hill EJ, Dineley KT, Parri HR. $\alpha 7$ Nicotinic receptor-mediated astrocytic gliotransmitter release: A β effects in a preclinical Alzheimer's mouse model. *PLoS One*. 2013; 8(11):e81828. eCollection 2013. [PubMed: 24312364]
105. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. *J Cell Biol*. 2005; 171:1001–1012. [PubMed: 16365166]
106. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante RJ, Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. *Hum Mol Genet*. 2010; 19:3053–3067. [PubMed: 20494921]
107. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. *Proc Natl Acad Sci U S A*. 2009; 106:22480–22485. [PubMed: 20018729]
108. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, Li XJ. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. *J Biol Chem*. 2010; 285:10653–10661. [PubMed: 20145253]
109. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Hausteine MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV, Khakh BS. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. *Nat Neurosci*. 2014; 17:694–703. [PubMed: 24686787]
110. Jiang R, Diaz-Castro B, Looger LL, Khakh BS. Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington's disease model mice. *J Neurosci*. 2016 in press.
111. Halassa MM, Haydon PG. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. *Annu Rev Physiol*. 2010; 72:335–355. [PubMed: 20148679]
112. Han X, Chen M, Wang F, Windrem M, Wang S, Shanz S, Xu Q, Oberheim NA, Bekar L, Betstadt S, Silva AJ, Takano T, Goldman SA, Nedergaard M. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. *Cell Stem Cell*. 2013; 12:342–353. [PubMed: 23472873]
113. Nimmerjahn A, Bergles DE. Large-scale recording of astrocyte activity. *Curr Opin Neurobiol*. 2015; 32:95–106. [PubMed: 25665733]

Highlights

- Astrocytes display intracellular Ca²⁺ signals
- Improved methods have unearthed new types of astrocyte Ca²⁺ signals
- Astrocyte basal Ca²⁺ levels are variable
- *In vivo* studies suggest astrocytes display behaviorally relevant Ca²⁺ signaling
- Astrocyte Ca²⁺ signaling is altered in neurodegenerative diseases

Outstanding Questions

Molecular/Cellular

- What are the molecular pathways that mediate various Ca^{2+} signals in astrocytes?
- What are the role(s) of organelles, other than ER, for astrocyte Ca^{2+} signals?
- What is the full set of molecular and physiological processes within astrocytes that Ca^{2+} controls?
- Can new genetic methods be developed to broadly suppress astrocyte Ca^{2+} signals in defined brain areas?

Circuits

- Are the functions of basal Ca^{2+} levels separable from those of Ca^{2+} elevations?
- What are the correlative relations between astrocyte Ca^{2+} signals and neural circuit function and mouse behavior?
- What are the causative functions of astrocyte Ca^{2+} signals for circuits and behavior?
- Do astrocyte Ca^{2+} signals serve distinct functions in distinct circuits?

Disease

- Can astrocyte biology be exploited to produce desirable effects in neural circuits associated with specific brain disorders?
- Do altered astrocyte Ca^{2+} signals contribute to specific neurodegenerative diseases?




Figure 1. GCaMPs

(A) Structure of GCaMP showing the modular nature of the molecule and the locations of mutations in different GCaMP6 variants relative to GCaMP5G. The panel is reproduced from the paper reporting the development of GCaMP6f [24]. (B) Excitation and emission spectra of GCaMP6f in solution in the absence and presence of Ca^{2+} . The spectra were provided by the Janelia GENIE Project; further biophysical properties have been published [24].




Figure 2. Key Figure: Ca^{2+} transport in cells

The cartoon shows various sources and sinks for Ca^{2+} in cells. In going forward, these need to be considered carefully in studies of astrocytes. Changes in cytosolic Ca^{2+} are dynamically regulated through interplay between Ca^{2+} channels, pumps and transporters. A variety of Ca^{2+} channels exist which are expressed on both the plasma membrane and the membrane of organelles. Voltage-gated Ca^{2+} channels are highly selective plasma membrane proteins that mediate Ca^{2+} signals in excitable cells in response to membrane depolarization. A number of neurotransmitters mediate Ca^{2+} signals through less-selective ligand-gated ion

channels. These include cell surface P2X receptors activated by ATP and the NMDA class of ionotropic receptors for glutamate (NMDAR). Nicotinic acetylcholine (AChR) and 5-HT₃ (5HT_{3R}) receptors are Ca²⁺-permeable members of the cys-loop family of ligand-gated ion channels activated by acetylcholine and 5-HT, respectively. TRP channels constitute a large family of widely expressed ion channels. They are divided into 6 families in mammals. Their Ca²⁺ selectivity varies widely and they are activated by a number of intracellular and extracellular cues including heat (e.g. TRPV1), cold (e.g. TRPM8), pungent chemicals (TRPA) and Ca²⁺ itself (TRPP2). TRPC channels are activated upon receptor-mediated signaling downstream of phospholipase C signaling via diacylglycerol in some cases. Orai channels are highly Ca²⁺-selective channels activated by the ER Ca²⁺ sensor STIM upon depletion of ER Ca²⁺ stores. Plasma membrane Ca²⁺ ATPase (PMCA) pumps and sodium-calcium exchangers (NCX) transport Ca²⁺ out of the cytosol. IP₃ receptors are intracellular Ca²⁺-permeable channels localized predominately to the ER where they mediate Ca²⁺ signals in response to IP₃ produced upon phospholipase C activation, which occurs downstream of GPCR activation. Receptor stimulation also elevates levels of cyclic ADP-ribose (cADPR) which activates the related ryanodine receptors (RyR). The ER Ca²⁺ stores are filled by sarco-endoplasmic reticulum Ca²⁺ ATPases (SERCA). The Golgi complex (not shown) also acts as a dynamic Ca²⁺ store housing IP₃ and ryanodine receptors for Ca²⁺ release and secretory pathway ATPases (together with SERCA) for filling. In addition to the ER, a number of acidic organelles which include lysosomes also serve as Ca²⁺ stores. These acidic Ca²⁺ stores express two-pore channels (TPCs), activated by the intracellular messenger NAADP, and TRPM2 activated by ADP-ribose (which additionally activates plasma membrane TRPM2). TRP mucolipins (TRPML) and P2X₄ receptors are also expressed on lysosomes. Ca²⁺ is also dynamically regulated by mitochondria. Ca²⁺ is rapidly taken up by the mitochondrial uniporter (MCU) which is a Ca²⁺-permeable channel localized to the inner mitochondrial membrane. Ca²⁺ is slowly released back into the cytosol by the actions of a mitochondrially targeted sodium-calcium changer (NCLX). The Ca²⁺ concentrations for the intracellular compartments were taken from published work [58-60].




Figure 3. Ca^{2+} signals in hippocampal astrocytes from wild type and $\text{Ip3r2}^{-/-}$ mice
(A) Schematic illustrating the experimental approach. AAVs were microinjected *in vivo*, brain slices were imaged ~ 2 weeks later and Ca^{2+} signals analyzed in a semi automated manner using custom software called GECIquant. **(B)** Representative images and traces for Ca^{2+} signals measured in an astrocyte from a *WT* mouse. Three predominant types of Ca^{2+} signal are demarcated: somatic signals (green), waves (red) and microdomains (yellow). Approximate territory boundaries are outlined in blue. **(C)** As in B, but for two astrocytes from an $\text{Ip3r2}^{-/-}$ mouse; somatic signals are largely absent, but many signals persist in branches. Figure from a recent paper [38].




Figure 4. Astrocyte basal Ca²⁺ levels are developmentally regulated

(A) Characteristic Ca²⁺ concentration map in a gap junction-coupled astrocyte from a mouse aged 15 days. Note that the Ca²⁺ concentration increases towards the branches. (B) Distribution of resting Ca²⁺ in cellular compartments of gap junction-coupled astrocytes from images such as those in A. Two developmental ages are shown. The image is reproduced (with permission) from Figure 5 of a recent paper [82].

Table 1
Strategies to express GECIs in astrocytes

GECI	Expression approach	Ref
Cytosolic Yellow cameleon 3.60 mice	Transgenic mice driven by the S100 β promoter	[49]
Cytosolic GCaMP3 and GCaMP6f	AAV 2/5 using the GfaABC ₁ D promoter, <i>in utero</i> electroporation	[28, 31, 38, 42-44, 47]
Membrane tethered GCaMP3 and GCaMP6f (Lck tagged)	AAV 2/5 and GfaABC ₁ D promoter, <i>in utero</i> electroporation	[28, 31, 43, 44, 47]
Cytosolic GCaMP3 mice	Knock-in at the <i>ROSA26</i> locus	[37, 41]
Cytosolic YC-nano50 mice	Knock-in using tetracycline transactivator (tTa)-tet operator (tetO) strategy at <i>Actb</i> locus	[48]
Cytosolic GCaMP5G mice	Knock-in at the <i>Polr2a</i> locus	[53]
Cytosolic GCaMP6f and GCaMP6s mice	Knock-in mice at the <i>ROSA26</i> and <i>TIGRE</i> loci	[38, 56]

Note: GCaMP3, GCaMP5G and GCaMP6f display Ca²⁺ affinities of 345, 447 and 375 nM, and k_{off} values of 2.57, 2.52 and 3.93 s⁻¹, respectively [24]. The Ca²⁺ affinity for YC-nano50 is 50 nM [48] and that for Yellow cameleon 3.6 is 250 nM [57].